Touchstone
Last syncNov 1, 2026, 6:55 PM ET

ICLR

Icon Plc Health Care Services-Commercial Physical & Biological Research Russell 3000
$211.36Close $16.2BMarket cap $80.08 – $215.4852-week range

Highlights

Strengths

  • Leading the market RS 90 · stronger than 90% of stocks over 12 months
  • Near its high 2% below its 52-week high

Cautions

  • Trend not confirmed 7 of 8 conditions · 200-day not rising
  • Extended 5.1 ATR above its 50-day average

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Oct 27, 2026
Off 12-month high 2%
1wk up 14.1% price change
1mo up 24.3% price change
12-month return up 28% market up 11% · its own up 17%
F-score — — Not assessed
Altman Z″ 2.10 Moderate risk
P/E 70.6× price / earnings
PEG — P/E / EPS growth
P/B 1.8× price / book
Earnings yield up 2.4% EBIT / enterprise value
Cheaper than 61% of the market · cheap
Revenue growth up 1% year on year
EPS growth — latest quarter
Sales growth down 3% latest quarter · -4 pts
ROE up 2% return on equity
Free cash margin up 10% $862.0M FCF
D/E 0.31 long-term debt / equity
Net debt / EBITDA 2.7×
Interest cover 2.4×EBIT / interest
Piotroski tests

Repair signals

  • Long-term debt down 15% ($3.4B → $2.9B)

Trade setup

ATR% 4.5% $9.52 a day · 2×ATR $192.31
RS 90 / 99 vs the universe
Trend 7 / 8 200-day not rising
Relative volume 2.7× vs 50-day average
Up/down volume 1.16 50 sessions
Implied move — no scheduled report
Trend template · 7 of 8
  • 200-day average rising for a month: fails

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged
  • No restatement or impairment
  • Equity positive
  • Interest covered
  • No material dilution
  • Profits tracking cash
  • Margins and revenue not shrinking
Last reported Oct 27, 2026

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $8.3B +0.8% on FY2024
$0 $10B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $2.8B FY2021 · $5.5B FY2022 · $7.7B FY2023 · $8.1B FY2024 · $8.2B FY2025 · $8.3B
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $229.3M -69% on FY2024
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $332.3M FY2021 · $153.2M FY2022 · $505.3M FY2023 · $554.2M FY2024 · $739.1M FY2025 · $229.3M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $862.0M -23% on FY2024
$0 $2B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $527.1M FY2021 · $735.4M FY2022 · $421.2M FY2023 · $1.0B FY2024 · $1.1B FY2025 · $862.0M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross
  • Net 3%
  • Free cash 10%
0% 50% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Gross 29% · Net 12% · Free cash 19% FY2021 · Gross 28% · Net 3% · Free cash 13% FY2022 · Gross 29% · Net 7% · Free cash 5% FY2023 · Gross 29% · Net 7% · Free cash 13% FY2024 · Gross 29% · Net 9% · Free cash 14% FY2025 · Net 3% · Free cash 10%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $2.2B net debt
  • Cash
  • Long-term debt
$0 $10B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $840.3M · Long-term debt $348.5M FY2021 · Cash $752.2M · Long-term debt $5.4B FY2022 · Cash $288.8M · Long-term debt $4.6B FY2023 · Cash $378.1M · Long-term debt $3.7B FY2024 · Cash $538.8M · Long-term debt $3.4B FY2025 · Cash $647.3M · Long-term debt $2.9B
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 76.57m +45.0% since FY2020
82.50m 52.79m FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 52.79m FY2021 · 81.55m FY2022 · 81.72m FY2023 · 82.50m FY2024 · 80.76m FY2025 · 76.57m
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $2.8B $5.5B $7.7B $8.1B $8.2B $8.3B
Gross margin 29% 28% 29% 29% 29% —
Operating income $391.5M $378.5M $795.2M $904.7M $1.0B $442.8M
Net income $332.3M $153.2M $505.3M $554.2M $739.1M $229.3M
Net margin 12% 3% 7% 7% 9% 3%
Earnings per share $6.24 $2.25 $6.13 $6.70 $8.90 $2.90
Free cash flow $527.1M $735.4M $421.2M $1.0B $1.1B $862.0M
Free cash margin 19% 13% 5% 13% 14% 10%
Cash $840.3M $752.2M $288.8M $378.1M $538.8M $647.3M
Long-term debt $348.5M $5.4B $4.6B $3.7B $3.4B $2.9B
Shareholders' equity $1.9B $8.1B $8.5B $9.2B $9.4B $9.2B
Shares outstanding 52.79m 81.55m 81.72m 82.50m 80.76m 76.57m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Oct 27, 2026 Interim ↗ Sep 30, 2026 27d
Jul 30, 2026 Interim ↗ Jun 30, 2026 30d
Jun 23, 2026 Interim ↗ Mar 31, 2026 84d
May 27, 2026 Annual ↗ Dec 31, 2025 147d
Oct 23, 2025 Interim ↗ Sep 30, 2025 23d
Jul 24, 2025 Interim ↗ Jun 30, 2025 24d
May 2, 2025 Interim ↗ Mar 31, 2025 32d
Feb 21, 2025 Annual ↗ Dec 31, 2024 52d
Oct 25, 2024 Interim ↗ Sep 30, 2024 25d
Jul 25, 2024 Interim ↗ Jun 30, 2024 25d
Apr 25, 2024 Interim ↗ Mar 31, 2024 25d
Feb 23, 2024 Annual ↗ Dec 31, 2023 54d

Current reports

FiledDisclosed
Oct 27, 2026 Foreign issuer report ↗
Oct 27, 2026 Foreign issuer report ↗
Oct 8, 2026 Foreign issuer report ↗
Sep 9, 2026 Foreign issuer report ↗
Aug 20, 2026 Foreign issuer report ↗
Aug 18, 2026 Foreign issuer report ↗
Aug 6, 2026 Foreign issuer report ↗
Jul 31, 2026 Foreign issuer report ↗
Jul 30, 2026 Foreign issuer report ↗
Jul 29, 2026 Foreign issuer report ↗
Jul 22, 2026 Foreign issuer report ↗
Jun 26, 2026 Foreign issuer report ↗